drugset / Trial / NCT06571864
AL Amyloidosis and Anti-CD38-Daratunumab
NaSingle-groupOpen-labelTreatment
Summary
AL Amyloidosis and anti-CD38
Timeline
- Start
- 2022-01-02
- Primary completion
- 2024-01-02
- Completion
- 2024-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | Intravenous |